Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHo, Sharleneen_US
dc.contributor.authorWong, Joshua Guoxianen_US
dc.contributor.authorNg, Oon Teken_US
dc.contributor.authorLee, Cheng Chuanen_US
dc.contributor.authorLeo, Yee Sinen_US
dc.contributor.authorLye, David Chien Boonen_US
dc.contributor.authorWong, Chen Seongen_US
dc.identifier.citationHo, S., Wong, J. G., Ng, O. T., Lee, C. C., Leo, Y. S., Lye, D. C. B. & Wong, C. S. (2020). Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults. AIDS Research and Therapy, 17(1).
dc.description.abstractBackground: The anti-retroviral combination of abacavir/lamivudine plus rilpivirine (ABC/3TC/RPV) is not recommended by international guidelines as the first-line regimen. However, it is potent, well-tolerated, and affordable, especially in resource-limited settings. This study evaluates the efficacy and safety of ABC/3TC/RPV as an initial regimen for treatment-naïve HIV-1 infected patients. Methods: A retrospective study was conducted in the largest HIV care centre in Singapore, with data collected June 2011 to September 2017. All treatment-naïve HIV-1 infected adults prescribed ABC/3TC as part of their initial anti-retroviral therapy regimen were included. The third drug was a non-nucleoside reverse-transcriptase inhibitor (NNRTI) such as RPV or efavirenz (EFV ), or boosted protease-inhibitor (PI). Patients were followed up for 48 weeks. The primary end-point was the percentage of patients achieving virologic suppression, analysed using on-treatment analysis. Secondary outcomes included CD4-count change, treatment discontinuation and treatment-related adverse events. Results: 170 patients were included in the study, 66 patients in the RPV group, 104 patients in the comparator group (EFV or boosted PI). 96% (n =24) in the RPV group and 87% (n =26) in the comparator group achieved viral suppression at 48 weeks (p =0.28). Median (interquartile range) time to viral suppression was similar: 17 (14–24) weeks in the RPV group, and 21 (13–26) weeks in the comparator group. There were no statistically significant differences in the CD4 count between the two groups. 14% (n =9) of patients on RPV discontinued treatment before 48 weeks, com-pared to 30% (n =31) from the comparator group (p =0.053). Of these, 23 discontinuations were due to drug adverse effects, and only 1 attributed to RPV (p < 0.01). One patient in each group had virologic failure. Conclusion: RPV is effective, safe and considerably more tolerable than compared to NNRTI or boosted PI in ABC/3TC-containing regimens for treatment-naïve patients. It offers an affordable and attractive option, especially in resource-limited settings.en_US
dc.relation.ispartofAIDS Research and Therapyen_US
dc.rights© 2020 The Author(s). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.en_US
dc.titleEfficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adultsen_US
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en_US
dc.description.versionPublished versionen_US
item.fulltextWith Fulltext-
Appears in Collections:LKCMedicine Journal Articles
Files in This Item:
File Description SizeFormat 
s12981-020-00272-5.pdf2.1 MBAdobe PDFThumbnail

Citations 50

Updated on Nov 29, 2023

Web of ScienceTM
Citations 50

Updated on Oct 31, 2023

Page view(s)

Updated on Dec 1, 2023

Download(s) 50

Updated on Dec 1, 2023

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.